We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -68.00 | -0.60% | 11,276.00 | 11,314.00 | 11,320.00 | 11,350.00 | 11,232.00 | 11,248.00 | 3,209,753 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8406 | 29.47 | 175.89B |
From Feb 2020 to Feb 2025
By Razak Musah Baba
LONDON--Valeant Pharmaceuticals International Inc. (VRX) will make a $130 million milestone payment to AstraZeneca PLC (AZN) following the U.S. Food and Drug Administration's approval of AstraZeneca's psoriasis drug, Siliq.
AstraZeneca has granted Valeant, an expert in dermatology, the exclusive license to develop and commercialize Siliq globally, except in Europe, Japan and some other Asian countries.
Under the terms of the agreement, AstraZeneca will receive $130 million from its U.S. partner after the first regulatory approval.
The FDA has approved Siliq (brodalumab) injections for the treatment of moderate-to-severe plaque psoriasis in adults.
AstraZeneca and Valeant are set to share profits from Siliq sales in the U.S.
AstraZeneca shares at 1220 GMT were down 1.7 pence, or 3.6%, at 45.15 pounds, valuing the company at GBP57.11 billion ($71 billion).
-Write to Razak Musah Baba at razak.baba@wsj.com
(END) Dow Jones Newswires
February 16, 2017 08:14 ET (13:14 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
